CHAMBER OF COMMERCE ISRAEL - UKRAINE’s Post

🚨 Theranautilus is reinventing the oral healthcare industry with nanobots Theranautilus raised $1.2M led by pi Ventures at a ₹60 crore valuation. Founded at IISc Bengaluru by Prof. Ambarish Ghosh, Dr. Debayan Dasgupta, and Dr. Shanmukh Srinivas, the startup uses nanorobots to solve dental issues like hypersensitivity in just 10 minutes. Funds will go toward building an ISO-certified facility, human trials in 2025, and IP filings. Products targeting both B2B and B2C markets aim to disrupt the $6B oral healthcare industry. Their vision is to revolutionize healthcare with nanorobotics, starting with oral health and advancing to life-threatening diseases like cancer. #Nanotech #HealthTech #DentalCare #Startups #Innovation #IISc Read more 👇 https://lnkd.in/gW-t_YU3 

Bionaut Labs raises an extension round in preparation for micro-robot clinical trials Bionaut is building micro-robots that precisely deliver drugs to hard-to-reach areas in the human brain. The company’s goal is to build “an elegant solution…that can reach places in the body we previously just couldn’t go,” said Bionaut CEO and cofounder Michael Shpigelmacher. So far, the company’s animal testing has been successful, and Bionaut has now raised more cash in anticipation of what will be the company’s biggest challenge yet: human clinical trials later this year. Fortune can exclusively report that Bionaut’s raised an extension round, which involved the Mayo Clinic, along with existing investors Khosla Ventures, Upfront Ventures, and OurCrowd. Fortune has also learned that Bill Gates’ Gates Ventures has invested, per two sources familiar with the matter. (A Gates Ventures representative didn’t return two requests for comment.) To date, Bionaut has raised over $70 million, Fortune can confirm. In 2022, the company closed its Series B, led by Khosla, bringing the total the company had raised by then to $63.2 million, according to Crunchbase. Bionaut declined to disclose valuation. Bionaut’s micro-robot is about the size of a grain of rice and is meant to move through the human body’s bloodstream and tissue to deliver drugs far more accurately than we can today. The micro-robot is controlled through magnetism—Bionaut’s scientists and engineers move the robot through the body by tweaking the electromagnetic field. "We think that this paradigm that we're bringing in time could spawn a whole different generation of ways to treat diseases,” said Shpigelmacher, who previously cofounded PrimeSense, a 3D sensor technology company acquired by Apple in 2013 for a reported $345 million (some reports suggested as much $360 million or $400 million). PrimeSense’s technology became FaceID. Eventually, the company aims to deliver a wide range of treatments dispersed throughout the body via “the Bionaut.” This in mind, Bionaut’s total addressable market is unknowable, but “any number you came up with would be big enough to justify the investment,” said Samir Kaul, Khosla Ventures founding partner and managing director. OurCrowd CEO and founder Jonathan Medved echoed that sentiment: "What I'm hoping for is that one tenth of the potential is realized.” In the near-term, the company has decided to focus on the area most requiring precision drug delivery: the brain, with the goal of treating diseases like cancer and Parkinson’s. However, the first use case the company is bringing to bear in clinical trials will be comparatively simple: Dandy-Walker Syndrome, a condition characterized by accumulating brain fluid. https://lnkd.in/dKP2Ecwr

#CA-based Carpl secures $6million in #funding. This round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from leading #strategic angel investors. Their #heartfelt #gratitude to all those who’ve been part of this incredible journey! They look forward to #expanding the team in North America and continuing to build their tech stack. CARPL.ai is used by the world’s top #healthcare organizations like the Singapore Government, Massachusetts General Hospital, Radiology Partners, University Hospitals, I-MED Radiology, Albert Einstein Hospital, and Clinton Health Access Initiative, to name a #few. They are also creating an impact in the #public health space by working with the Government of India to enable large-scale Tuberculosis Screening Programmes in the most remote regions of the #country. A recent joint statement by the world’s top #radiology associations also brings to light the importance of validation, deployment and #monitoring of AI while being used in clinical #practice. Radiologists can access, evaluate, and #incorporate radiology artificial intelligence (AI) solutions into their clinical practices using the vendor-neutral CARPL.ai platform. In clinical radiology #workflows, CARPL offers a single user interface, a single data channel, and a single #procurement channel for the testing, implementation, and oversight of AI solutions. CARPL - Radiology AI Platform Stellaris Venture Partners Radiology Partners Alok Goyal Vidur Mahajan To share your startup story write us on - [email protected] #carpl #funding #startup

👀👀👀 Kirurški sanatorij Rožna dolina d.o.o. and HealthChain I3 are looking for two Slovenian small and medium-sized enterprises (SME) or #startups to address two #healthcare #challenges. These SMEs will become full partners of the HealthChain Consortium, receiving tailored training and funding. The targeted beneficiaries must be located within the same country as the Healthcare Organisation proposing the challenge. 💡 The first challenge, #HIPRO, aims to improve #hip surgery patients safety after fast-track surgery and discharge from hospital (and therefore improving their quality of life). 💡 The second challenge, #MEPRO, aims to improve patient self-assessment and safety after discharge from hospital (and quality of life). The Challenger also wants to learn the acceptance of tailored medical mobile solutions in elderly and to learn how to easily integrate 3rd party mobile solutions through its corporate IT system. 👉 You will find the link to apply to these challenges in the first comment below.

ARC Innovation is a Breeding Ground for Innovation: A major success story with the acquisition of Innovalve Bio Medical Ltd. by Edwards Lifesciences. This acquisition marks another successful exit for a company cultivated within ARC Innovation, Sheba Medical Center, Tel Hashomer’s dedicated program for fostering healthcare innovation. Founded in 2017 at ARC Innovation, Innovalve Bio Medical Ltd. has been at the forefront of developing a minimally invasive approach to mitral valve replacement. Their innovative artificial mitral valve is designed to be implanted using a catheter, minimizing surgical trauma for patients with heart disease. The technology has already received FDA approval for initial human trials, with over 40 successful surgeries performed to date. ARC Innovation fosters a collaborative environment where clinicians and inventors can work together to translate groundbreaking ideas into real-world solutions. ARC has launched Shoni Health Ventures a new healthtech VC fund that will invest in early-stage (pre-seed and seed stage) digital health and medical device startups. Led by Eran Lerer, Shoni Health Ventures offers essential support and resources to entrepreneurs as they build and grow their ventures. Eyal Zimlichman, MD Daphna Deane benny ben lulu Gal Goshen Orli Biger Angel W. Rabinovich Avner Halperin Ehud Raanani Boris Orlov Shlomo Noy Sylvie Luria https://lnkd.in/gb9_jeQH

CytoVeris is honored to be selected as a part of the 2024 MedTech Innovator cohort – MedTech Innovator is the world’s largest accelerator of medical technology companies: This was a particularly competitive year, with around 1,400 applying for approximately 65 spots in this year's final cohort.  Explore the full list of participating companies here: https://lnkd.in/eq8zbHmR We look forward working with industry experts to further our mission to bring enhanced tissue ID and cancer margin visualization to MIS & robotic procedures. #MedTechInnovator #CytoVeris #Cancersurgery #AI #Labelfree #autofluorescence #cancermargin#multispectral #intraoperativeimaging #Advancedvisualization #Precisionsurgery #metech #cancerdetection#enhancedimaging #roboticsurgery

Hot off the press! The latest edition of The Memo, featuring John Slump, Co-Founder & CEO of Atraverse Medical, Inc. is out now. Here’s a preview of this week’s edition of our weekly newsletter, The Memo: Co-founded by John Slump, Eric Sauter, and Dr. Steven Mickelsen, Atraverse Medical is on a mission to improve patient outcomes with its radiofrequency guidewire. Origin Story The inception of Atraverse Medical is a story of three seasoned entrepreneurs reuniting to pioneer a next-generation transseptal access device. John Slump, Eric Sauter, and Dr. Mickelsen met over a decade ago while working on a previous startup, FARAPULSE™ which was acquired by Boston Scientific in 2021. "We’ve already gone through one of these things and come out the other end as friends, wanting to do it again," says John Slump, reflecting on their prior experience. The timing of it all worked in their favor too. "We had a perfect storm with both Dr. Mickelsen and Eric Sauter leaving their prior endeavors and having an idea for a best-in-class left-heart access device," Slump explains. The three looked at the success of FARAPULSE™, combined with their camaraderie, and laid the groundwork for their next venture. The inspiration for Atraverse Medical came from observing the shifting market dynamics in Electrophysiology and Structural Heart procedures, some of the fastest-growing medical device segments. These procedures rely on safe, efficient, and precise access to the left side of the heart. The foundation of Atraverse was to deliver the next generation of innovation in the category to improve patient safety and outcomes in these critical procedures. The Current Landscape The traditional methods of left-heart access can be complex, time-consuming, and carry risks of complications such as mislocation of the crossing site or damage to cardiac tissues. Left-heart access is crucial for nearly two million procedures each year. “There are approximately 1.5 to 2 million procedures each year that require accessing the left side of the heart from the right side to deliver therapies such as atrial fibrillation ablation or left atrial appendage occlusion,” Slump adds. Continue Reading: https://lnkd.in/gFThDMxQ

“Buy to build” - acquiring an entity with aspirations of resourcing and scaling. A topic from Holly Scott’s weekly curation of #medtech news! A lot has been written about the Johnson & Johnson MedTech and Auris Health, Inc. ruling. I don’t know enough to comment intelligently on it per se. But I can speak to the excitement of M&A and then the challenges of the integration. It’s a new relationship between companies, people, fundamental processes and the customers. On the one hand, there’s the sexy stuff from the vantage point of the acquirer - org structures, go to market planning, rosy financial forecasts, and the pride of an expanded footprint and achievement. Often forgotten are the success mandatories of IT, billing, financial integration, customer service, internal process flow training and normalization - all of which can take years. And the last thing on the acquiring team’s mind is culture, talent development and integration. For those who have been acquired, they need to assume a new identity (going from director of shipping and logistics for company X to now shipping manager for site Y of company Z) and assimilate to new norms by observation and trial-and-error. This is a big, intangible piece and its impact plays out over years of employee engagement scores. “M&A can get messy and chaotic” is an understatement. ————— Social media and LinkedIn can bring leaders from around the world into your professional life. I look for content from Holly Scott, Joe Mullings, Kevin Berchelmann, Don Manser and Devin Stanley to build out my thinking. Who influences you? Who do you choose? #leadership #changinglives #dothething

In this Sunday's edition, serial medtech entrepreneur Paul Buckman talks about the proven strategies he's utilized across multiple successful startups. Paul made a leap from his position as President of Boston Scientific's cardiology business to play significant roles at early-stage companies like ev3 and Pathway. And Shaun R. Bagai, CEO of RenovoRx, shares his cross-functional experiences across clinical research, marketing, sales, and market development. Here’s a sneak peek at two of our exclusive interviews: 𝗛𝗼𝘄 𝗥𝘂𝘁𝗵𝗹𝗲𝘀𝘀 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗖𝗮𝗻 𝗛𝗲𝗹𝗽 𝗠𝗲𝗱𝘁𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗣𝗮𝘂𝗹 𝗕𝘂𝗰𝗸𝗺𝗮𝗻, 𝗙𝗼𝗿𝗺𝗲𝗿 𝗖𝗘𝗢 𝗼𝗳 Conventus Orthopaedics 𝗮𝗻𝗱 𝗦𝗲𝗻𝘁𝗿𝗲𝗛𝗘𝗔𝗥𝗧 🚩 How Conventus converted orthopedic surgeons who were used to open surgeries with plates and screws, to adopt the startup's minimally invasive technology for fracture repairs. 📝 The priority checklist Paul's startup R&D teams used during early product development to continuously assess where to allocate resources. 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗡𝗲𝘄 𝗠𝗮𝗿𝗸𝗲𝘁𝘀 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗩𝗮𝗹𝘂𝗲 𝗼𝗳 𝗖𝗿𝗼𝘀𝘀-𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲: 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗦𝗵𝗮𝘂𝗻 𝗕𝗮𝗴𝗮𝗶, 𝗖𝗘𝗢 𝗼𝗳 𝗥𝗲𝗻𝗼𝘃𝗼𝗥𝘅 🔓 How Shaun and his team developed a new market for hypertension in Germany during his time at Ardian. ❤️🩹 Shaun's approach to reviving HeartFlow's failed study that eventually helped drive the adoption of the technology. PS - We recently launched exciting new features exclusively for Medsider premium members: ⭐ Playbooks: Go from 0 to 100 with hand-picked collections of the best Medsider interviews with the brightest founders and CEOs. ⭐ Investor database: Find your next medical device or health technology investor with our growing database of VC funds, equity investors, and high-net-worth angels.

From a kidney doc’s POV: Building upon lessons learned from last week’s AV Health & Bio Startup class. Enke Bashllari, Ph.D. Evaluating the cap table for a company is like doing ICU rounds. We know which patient has the best likelihood to be discharged home (a successful exit); those who may need dialysis; and labs that are unfortunately, DOA. 3 main startup vital signs to tell if it has a good baseline prognosis: 1. Cap table alignment - • Equity is not evenly distributed. Sensible allocation of one’s contribution should match your piece of the pie.  • Equity is based on “Skillsets around the Table” not our “knowledge-set” While our ideas may be founded on lifelong learning, it carries little weight in company value and thereby ownership. Top billing goes to the ability to develop software as a service, implement streamlined processes and sell their products to us or our patient population for use. • Who’s in charge? When medical decisions are at a crossroads, ultimately the attending physician on record makes the final call. In a cap table, look for the one who owns the most equity. In order to get the lion’s share for the work you do, become a physician-founder. Otherwise, industry standard is to expect to get less than 2% of the company as an advisor. 2. Vesting - is like a work-marriage agreement to hold yourself and others accountable. As founder, it’s your skin in the game. You’ll be dedicating at least 5-10 years of known uncertainty in the startup world. Best to marry well, but anything goes sideways, you have a solid prenup in place. 3. Deadweight on the cap table - No one invests in a company on life support. Obviously there was a Co-founder mismatch. Choose your team wisely and objectively assess their proportional contribution to the total valuation. Docs, we are the optimal user-innovators. We solve pain points based on decades of understanding patient’s needs and make innumerable individual medical decisions every day. Plus, we can curbside a medical network of friends and colleagues anytime for further validation. Who knows our job and patients better than we who have a 1:1 relationship in caring for them? Lastly, it’s no secret we are overburdened with doing admin work like charting, billing and faxing(!) the latest version of standard busy paperwork. What the system doesn’t allow for is for us to have the resources and protected time to innovate. Any practicing doctor in private practice who does her own billing knows exactly what we need to make our lives more efficient. Find a way to take tasks off our plate so our time can be wisely spent fixing what’s broken. Invest in this and watch an army of unicorns transform healthcare.